The trial tested Empliciti with Revlimid and dexamethasone in newly diagnosed patients ineligible for bone marrow transplant. Although approved in relapsed/refractory disease, Empliciti has not kept pace on the market with other myeloma drugs.
BMS's acquisition of Celgene had attracted opposition from two institutional investors. However, one of them withdrew its effort to derail the deal despite continuing to voice opposition.
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
In a call to following news of the deal, executives pointed to near-term launch opportunities and pipelines, but some analysts expressed concern about the loss of patent protection for Revlimid and Opdivo.
The acquisition brings together two of the largest drugmakers in the country, both of which are major players in biopharma, particularly oncology.
Janssen halts lung cancer and myeloma trials, citing lack of clinical benefit and greater number of patient deaths in combo arm.
A KHN analysis found that 47 of the drugs cost Medicare and Medicaid almost $12 billion in 2016. The spending totals don’t include rebates, which drugmakers return to the government after paying for the drugs upfront but are not public.
Arbiter’s Anjali Jameson on hospital and payer alignment.
The FDA commissioner is singling out companies that he says have blocked access to product samples needed to make generics.